Skip to main content
padlock icon - secure page this page is secure

Open Access Long-term omalizumab use in the treatment of exercise-induced anaphylaxis

Download Article:
(HTML 26.7 kb)
(PDF 50.9 kb)
Reported is a case of a 39-year-old male who was diagnosed with exercise-induced anaphylaxis (EIA). He was initially treated prophylactically with fexofenadine, montelukast, and ranitidine. He also used an epinephrine autoinjector as needed. He was refractory to these medications and continued to have episodes of EIA. He was then started on a trial of omalizumab, an immunoglobulin E monoclonal antibody, and had resolution of the EIA episodes. After discontinuation of the omalizumab, the EIA episodes returned. He was restarted on omalizumab and since that time, has had 5 years free of EIA episodes and can now exercise without any symptoms. To our knowledge, this is only the third case in the literature of successful treatment of EIA by using omalizumab. This case was unique because it provided successful long-term use of omalizumab for EIA. Further studies are recommended for the use of omalizumab in the treatment of EIA.
No References for this article.
No Supplementary Data.
No Article Media
No Metrics

Keywords: Anaphylaxis; Omalizumab; angioedema; epinephrine; exercise-induced anaphylaxis; food dependent exercise-induced anaphylaxis; gliadin; mast cell activation; urticaria

Document Type: Research Article

Affiliations: From the Department of Allergy and Immunology, Wilford Hall Abulatory Surgical Center, Lackland AFB, San Antonio, Texas

Publication date: 01 October 2017

More about this publication?
  • Allergy and Rhinology will no longer be hosted on Ingenta Connect as of July 10, 2018. For all subscription orders where the customer's end-user address is in the USA, Canada, Central and South America including the Caribbean, please contact [email protected] For all subscription orders where the customer's end user address is in the UK, Europe, Middle East, Africa and Australasia, please contact [email protected]
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more